FDA Approved Products

Application #TypeSponsorNotesProduct #Drug NameFormStrengthActive IngredientApproval DateMarketing StatusReference Standard
216457NDAHERON THERAPS INC001APONVIEEMULSION;INTRAVENOUS32MG/4.4ML (7.2MG/ML)APREPITANT2022-09-16PrescriptionYes
211988NDAHERON THERAPS INC001ZYNRELEF KITSOLUTION, EXTENDED RELEASE;PERIARTICULAR60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML)BUPIVACAINE; MELOXICAM2021-05-12DiscontinuedNo
002ZYNRELEF KITSOLUTION, EXTENDED RELEASE;PERIARTICULAR200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML)BUPIVACAINE; MELOXICAM2021-05-12PrescriptionYes
003ZYNRELEF KITSOLUTION, EXTENDED RELEASE;PERIARTICULAR300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML)BUPIVACAINE; MELOXICAM2021-05-12DiscontinuedNo
004ZYNRELEF KITSOLUTION, EXTENDED RELEASE;PERIARTICULAR400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML)BUPIVACAINE; MELOXICAM2021-05-12PrescriptionYes
209296NDAHERON THERAPS INC001CINVANTIEMULSION;INTRAVENOUS130MG/18ML (7.2MG/ML)APREPITANT2017-11-09PrescriptionYes
022445NDAHERON THERAPS INC001SUSTOLINJECTABLE;SUBCUTANEOUS10MG/0.4ML (10MG/0.4ML)GRANISETRON2016-08-09PrescriptionYes